BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15668286)

  • 1. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.
    Lapointe R; Létourneau R; Steward W; Hawkins RE; Batist G; Vincent M; Whittom R; Eatock M; Jolivet J; Moore M
    Ann Oncol; 2005 Feb; 16(2):289-93. PubMed ID: 15668286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
    J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.
    Dent SF; Arnold A; Stewart DJ; Gertler S; Ayoub J; Batist G; Goss G; Nevile A; Soulieres D; Jolivet J; McLntosh L; Seymour L
    Lung; 2005; 183(4):265-72. PubMed ID: 16211462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
    J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troxacitabine: BCH 4556, SPD 758, Troxatyl.
    Adis International Ltd
    Drugs R D; 2003; 4(4):264-8. PubMed ID: 12848594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
    Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
    Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
    BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
    Giles FJ; Feldman EJ; Roboz GJ; Larson RA; Mamus SW; Cortes JE; Verstovsek S; Faderl S; Talpaz M; Beran M; Albitar M; O'Brien SM; Kantarjian HM
    Leuk Res; 2003 Dec; 27(12):1091-6. PubMed ID: 12921945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
    Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
    J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
    Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F
    Leuk Lymphoma; 2007 Jan; 48(1):39-45. PubMed ID: 17325846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
    Weitman S; Marty J; Jolivet J; Locas C; Von Hoff DD
    Clin Cancer Res; 2000 Apr; 6(4):1574-8. PubMed ID: 10778991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
    Jimeno A; Messersmith WA; Lee CK; Ma WW; Laheru D; Donehower RC; Baker SD; Hidalgo M
    Ann Oncol; 2008 Feb; 19(2):374-9. PubMed ID: 18245131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Troxacitabine].
    Gourdeau H; Jolivet J
    Bull Cancer; 2004 Mar; 91(3):213-8. PubMed ID: 15171046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
    Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
    J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
    Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L
    J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
    Lin CC; Beeram M; Rowinsky EK; Takimoto CH; Ng CM; Geyer CE; Denis LJ; De Bono JS; Hao D; Tolcher AW; Rha SY; Jolivet J; Patnaik A
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):167-75. PubMed ID: 19449006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troxacitabine prodrugs for pancreatic cancer.
    Adema AD; Radi M; Daft J; Narayanasamy J; Hoebe EK; Alexander LE; Chu CK; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1073-7. PubMed ID: 18058539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
    Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.